Skip to main content

Table 2 Patient accountability

From: Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results

  FPV/r + ABC/3TC EFV + ABC/3TC
ITT:Exposed population, n 51 50
Completed 96 weeks on study, n (%) 34 (67%) 33 (66%)
Discontinued study, n (%) 17 (33%) 17 (34%)
 Adverse event 3 (6%) 2 (4%)
 Lack of efficacy 5 (10%) 5 (10%)
 Non-compliance with protocol treatment 3 (6%) 2 (4%)
 Lost to follow-up 6 (12%) 6 (12%)
 Withdrew consent 0 2 (4%)
  1. Abbreviations: ABC/3TC abacavir/lamivudine, EFV efavirenz, FPV/r fosamprenavir/ritonavir, ITT intent-to-treat.